Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laurence Albiges-Sauvin

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Expert Review of Anticancer Therapy|January 11, 2014
Clinical implications of body composition assessment by computed tomography in metastatic renal cell carcinomaSami Antoun, Emilie Lanoy, Laurence Albiges-Sauvin, et al.
Bulletin Du Cancer|June 15, 2011
[Cell cycle, mitosis and therapeutic applications]Antonin Levy, Laurence Albiges-Sauvin, Christophe Massard, et al.
Cancer|June 27, 2013
Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapiesSami Antoun, Emilie Lanoy, Roberto Iacovelli, et al.
Investigational New Drugs|April 22, 2011
Reappraisal of treatment-induced renal dysfunction in patients receiving antiangiogenic agents in phase I trialsAntonin Levy, Laurence Albiges-Sauvin, Christophe Massard, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Expert Review of Anticancer Therapy|January 11, 2014
Clinical implications of body composition assessment by computed tomography in metastatic renal cell carcinomaSami Antoun, Emilie Lanoy, Laurence Albiges-Sauvin, et al.
Bulletin Du Cancer|June 15, 2011
[Cell cycle, mitosis and therapeutic applications]Antonin Levy, Laurence Albiges-Sauvin, Christophe Massard, et al.
Cancer|June 27, 2013
Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapiesSami Antoun, Emilie Lanoy, Roberto Iacovelli, et al.
Investigational New Drugs|April 22, 2011
Reappraisal of treatment-induced renal dysfunction in patients receiving antiangiogenic agents in phase I trialsAntonin Levy, Laurence Albiges-Sauvin, Christophe Massard, et al.
Pageof 1